Opinion|Videos|October 14, 2024
Takeaways from the UH CINEMA Program
Key Takeaways
- UH CINEMA addresses the complex needs of patients with overlapping cardiovascular, renal, and metabolic conditions through integrated care models.
- Implementation challenges include coordinating multidisciplinary teams and managing resource allocation effectively.
A panel of cardiometabolic risk management experts analyzes key takeaways from the UH CINEMA Program.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Let’s discuss some initiatives we have championed at our institutions. What are these initiatives and how are they impacting the care of CRM patients? Dr. Neeland: Tell us about the University Hospitals Heart & Vascular Institute’s Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (UH CINEMA).
- How is the UH CINEMA program advancing health care for patients with overlapping heart, diabetes, and kidney issues?
- What challenges have you experienced implementing this program?
- What specific results can you share from this program?
- What are future opportunities to improve CRM care based on this program?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Advertisement
Related to this article
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Health Equity & Access Weekly Roundup: November 6, 2026
3
Medicaid Cuts and Caregiving in Congress: Andy Kim
4
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
5